BDR Lifesciences is a finished-dose manufacturer based in India. It holds 10 active US drug master files and 2 valid CEPs across a filed portfolio of 8 molecules. Its filings concentrate with CDSCO (India) and JFDA (JO). Its GMP standing is certified by CDSCO (India) and EMA. Customs aggregates show $27K of exports covering 2 molecules to 1 destination in 2025.
| Site | FDA FEI |
|---|---|
| Vadodara, India | 3009119873 |
| Luna Village, India | Not on file |
| taluka padra luna 391 440 vadodara, India | Not on file |
| taluka padraluna 391 440vadodara, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Avatrombopag | US FDA | 2 |
| Enzalutamide | US FDA | 2 |
| Nintedanib | US FDA | 2 |
| Olaparib | US FDA | 2 |
| Relugolix | US FDA | 2 |
| Sorafenib | EDQM, SFDA (Saudi Arabia) | 2 |
| Lapatinib Ditosylate | SFDA (Saudi Arabia) | 1 |
| Pemetrexed Disodium | EDQM | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 20 | 2 |
| JFDA (JO) | 1 | None |
| EMA | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $27K | 1 |
| 2024 | Not reported | $28K | 1 |
| 2023 | Not reported | $8K | 1 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. BDR Lifesciences comes back tiered against every other supplier able to file there.
Start for free